MDGL Stock Analysis: Buy, Sell, or Hold?
MDGL - Madrigal Pharmaceuticals, Inc. Common Stock
$516.59
3.71 (0.72%)
▲
5d:
+3.37%
30d:
+0.58%
90d:
+15.38%
BUY
HIGH Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When MDGL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: MDGL trading at deep discount. Market pricing in -27.5% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: MDGL trading at deep discount. Market pricing in -27.5% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$433.66
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$269.27
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: MDGL is currently trading at $516.59, which is considered slightly high relative to its 30-day fair value range of $479.14 to $519.00. From a valuation perspective, the stock is trading at a discount (Forward PE: 41.4) compared to its historical average (108.8). Remarkably, the market is currently pricing in an annual earnings decline of 27.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, MDGL is in a uptrend. The price is approaching resistance at $515.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MDGL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (12th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $678.71 (+32.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MDGL is in a uptrend. The price is approaching resistance at $515.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MDGL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (12th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $678.71 (+32.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$479.14 -
$519.00
Company Quality Score
60/100
(HOLD)
Options IV Signal
12th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
80.8%
All Signals
- BULLISH: Options cheap (IV 12th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 32.3% below Wall St target ($678.71)
Trading Range Analysis
30-Day Trading Range
$479.14 -
$519.00
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$38.13
(7.4%)
Support & Resistance Levels
Support Level
$460.89
Resistance Level
$515.00
Current Trend
Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
41.43
Wall Street Target
$678.71
(+32.3%)
Revenue Growth (YoY)
126.8%
Profit Margin
-27.3%
Valuation Discount vs History
-27.5% cheaper
PE vs Historical
41.4 vs 108.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-27.5%
(market-implied from PE analysis)
1-Year Target
$461.59
(-10%)
2-Year Target
$415.43
(-19%)
3-Year Target
$373.89
(-27%)
3-Yr Target (if PE normalizes)
(PE: 41→109)
$981.92
(+92%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 41.4 to 108.8
Stabilization Target:
$1346.94
(+162.6%)
PE Expansion Potential:
+162.6%
Share & Embed Analysis
Last updated: June 23, 2026 11:58 AM ET
Data refreshes hourly during market hours. Next update: 12:58 PM
Data refreshes hourly during market hours. Next update: 12:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDGL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
15
Sells
Net
INSIDERS SELLING
Recent Transactions
Mardi Dier
SELL
1982 shares
2026-03-06
Carole Huntsman
SELL
419 shares
2026-03-06
William John Sibold
SELL
1663 shares
2026-03-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 64 BUY |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 59 HOLD |
Advanced MDGL Option Strategies
Professional options setups generated by AI based on today's MDGL price and gamma walls.
